Research Article

You have full text access to this OnlineOpen article

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy

  1. Leen De Rycke*,
  2. Elli Kruithof,
  3. Nancy Van Damme,
  4. Ilse E. A. Hoffman,
  5. Nancy Van den Bossche,
  6. Filip Van den Bosch,
  7. Eric M. Veys,
  8. Filip De Keyser

Article first published online: 3 APR 2003

DOI: 10.1002/art.10876

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 48, Issue 4, pages 1015–1023, April 2003

Additional Information

How to Cite

De Rycke, L., Kruithof, E., Van Damme, N., Hoffman, I. E. A., Van den Bossche, N., Van den Bosch, F., Veys, E. M. and De Keyser, F. (2003), Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis & Rheumatism, 48: 1015–1023. doi: 10.1002/art.10876

Author Information

  1. Ghent University Hospital, Ghent, Belgium

*Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium

Publication History

  1. Issue published online: 3 APR 2003
  2. Article first published online: 3 APR 2003
  3. Manuscript Accepted: 19 DEC 2002
  4. Manuscript Received: 10 OCT 2002

Funded by

  • Vlaams instituut voor de bevordering van het wetenschappelijk-technologisch onderzoek in de industrie. Grant Number: IWT/SB/11127
  • Bijzonder Onderzoeksfonds Ghent University. Grant Number: BOF01/DCO/068
  • Bijzonder Onderzoeksfonds Ghent University. Grant Number: BOF00/DOC/031

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (87K)

REFERENCES

  • 1
    Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum 1999; 42: 415–20.
    Direct Link:
  • 2
    Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Lamour A, et al, Société de Rhumatologie de l'Ouest. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. J Rheumatol 1999; 26: 2622–7.
  • 3
    Callahan LF, Pincus T, Huston JW III, Brooks RH, Nance EP Jr, Kaye JJ. Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997; 10: 381–94.
    Direct Link:
  • 4
    Abu-Shakra M, Toker R, Flusser D, Flusser G, Friger M, Sukenik S, et al. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs. Arthritis Rheum 1998; 41: 1190–5.
    Direct Link:
  • 5
    McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 1999; 58: 156–63.
  • 6
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36: 1681–90.
    Direct Link:
  • 7
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10.
  • 8
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, et al. Therapeutic efficacy of multiple infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63.
    Direct Link:
  • 9
    Maini RN, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 345: 1932–9.
  • 10
    Lipsky PE, van der Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti–Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602.
  • 11
    Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27: 841–50.
  • 12
    Van den Bosch F, Kruithof E, de Vos M, de Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms. Lancet 2000; 35: 1821–2.
  • 13
    Van den Bosch F, Kruithof E, Baeten D, de Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of 3 infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428–33.
  • 14
    Brandt J, Haibel H, Cornely D, Golder W, Gonzales J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346–52.
    Direct Link:
  • 15
    Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755–65.
    Direct Link:
  • 16
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187–93.
  • 17
    Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 1029–35.
  • 18
    Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761–9.
  • 19
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398–405.
  • 20
    Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 1341–59.
  • 21
    Keane J, Gershon S, Wise RP, Miraibile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098–104.
  • 22
    Van den Bosch F, de Keyser F, Joos R, Kruithof E, Noe A, Baeten D, et al. Reactivation of tuberculosis in 2 patients with spondyloarthropathy treated with infliximab [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S78.
  • 23
    Centocor, Inc. Remicade (infliximab). Data on file.
  • 24
    Durez P, Devogelaer JP, van den Bosch F, Kruithof E, Perets A, Verbruggen L, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: clinical results in a Belgian observational cohort [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S83.
  • 25
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 26
    Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218–27.
    Direct Link:
  • 27
    Humbel RL. Detection of antinuclear antibodies by immunofluorescence. In: Van VenrooijWJ, MainiRN, editors. Manual of biological markers of disease. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1993. A2: p. 1–16.
  • 28
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7.
    Direct Link:
  • 29
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
    Direct Link:
  • 30
    Werle E, Blazek M, Fiehn W. The clinical significance of measuring different anti-dsDNA antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test. Lupus 1992; 1: 369–77.
  • 31
    Hylkema MN, Huygen H, Kramers C, van der Wal TJ, de Jong J, van Bruggen MC, et al. Clinical evaluation of a modified ELISA, using photobiotinylated DNA, for the detection of anti-DNA antibodies. J Immunol Methods 1994; 170: 93–102.
  • 32
    Von Mühlen CA, Tan EM. Autoantibodies in diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995; 24: 232–58.
  • 33
    Bootsma H, Spronk PE, Hummel EJ, de Boer G, ter Borg EJ, Limburg PC, et al. Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. Scand J Rheumatol 1996; 25: 352–9.
  • 34
    Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141–7.
  • 35
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9.
  • 36
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478–86.
  • 37
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93.
  • 38
    Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238–44.
  • 39
    Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763–9.
  • 40
    Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002; 61: 171–3.
  • 41
    Mease PJ, Goffe BS, Metz J, vander Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385–90.
  • 42
    Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346: 1349–56.
  • 43
    Immunex Corp. Enbrel (etanercept). Data on file.
  • 44
    Charles PJ, Smeenk RJT, de Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383–90.
    Direct Link:
  • 45
    Shakoor N, Michilska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579–80.
  • 46
    Brion PH, Mittal-Henkel A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999; 131: 634.
  • 47
    De Bandt MJ, Descamps V, Meyer O. Two cases of etanercept-induced systemic lupus erythematosus in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2001; 60: 175.
  • 48
    Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BHCh. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 2001; 40: 1317–9.
  • 49
    Misery L, Perrot JL, Gentil-Perret A, Pallot-Prades B, Cambazard F, Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 2002; 146: 334–5.
    Direct Link:
  • 50
    Sulcebe G, Morcka K. Diagnostic and prognostic significance of different antinuclear antibodies in more than 1000 consecutive Albanian patients with rheumatic diseases. Clin Exp Rheumatol 1992; 10: 155–61.
  • 51
    Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 1998; 18: 59–62.
  • 52
    Miltenburg AMM, Roos A, Slegtenhorst L, Daha MR, Breedveld FC. IgA anti-dsDNA antibodies in SLE: occurrence, incidence and association with clinical and laboratory variables of disease activity. J Rheumatol 1993; 20: 53–8.
  • 53
    Amoura Z, Koutouzov S, Piette JC. The role of nucleosomes in lupus. Curr Opin Rheumatol 2000; 12: 369–73.
  • 54
    Bernstein R. Autoantibodies to histones, Sm and ubiquitins. In: Van VenrooijWJ, MainiRN, editors. Manual of biological markers of disease. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1996. C2: p. 1–7.
View Full Article (HTML) Get PDF (87K)